Clover Corporation CEO on strong H1 results & product pipeline - ASX SMIDcaps Conference

Clover Corporation Limited (ASX:CLV) CEO & managing director Peter Davey talked with Proactive at the ASX Small and Mid-Cap Conference about the company’s technology-driven approach to delivering omega-3 and omega-6 nutritional solutions, and how this is supporting strong global growth. Davey explained that Clover specialises in microencapsulation technology, which allows oils such as fish, algal and fungal oils to be converted into powder form. This process removes taste and smell while preserving nutritional benefits, enabling integration into a wide range of food and beverage products. As he put it, “we effectively turn oil into powder,” making it easier to incorporate essential nutrients without compromising product quality. The company continues to innovate, including the development of its gel emulsion technology designed to improve product stability in non-refrigerated markets, particularly across Asia. Clover Corporation has also seen strong uptake in the US and ongoing testing across Asian markets. Financially, the company delivered a strong first half, reporting revenue growth of 17% to $44 million and improved margins. Davey highlighted expanding demand across Australia, New Zealand and Europe, alongside a solid balance sheet and increased inventory to support growth. Looking ahead, Clover Corporation is advancing new products such as its encapsulated choline solution, with commercialisation expected in the next financial year. With a global footprint and long-standing customer relationships, the company is positioning itself for continued expansion. For more insights, visit Proactive’s YouTube channel, like this video, subscribe, and enable notifications for future updates. #CloverCorporation #Omega3 #InfantNutrition #FoodTechnology #Microencapsulation #ASX #SmallCaps #Biotech #Nutraceuticals #InvestorUpdate #HealthTech #FoodInnovation #GlobalGrowth #CEOInterview